U.S. markets open in 6 hours 18 minutes
  • S&P Futures

    4,376.25
    +28.00 (+0.64%)
     
  • Dow Futures

    34,098.00
    +259.00 (+0.77%)
     
  • Nasdaq Futures

    15,090.50
    +81.00 (+0.54%)
     
  • Russell 2000 Futures

    2,197.50
    +20.70 (+0.95%)
     
  • Crude Oil

    71.25
    +0.96 (+1.37%)
     
  • Gold

    1,761.00
    -2.80 (-0.16%)
     
  • Silver

    22.22
    +0.05 (+0.23%)
     
  • EUR/USD

    1.1733
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    25.71
    +4.90 (+23.55%)
     
  • GBP/USD

    1.3672
    +0.0013 (+0.10%)
     
  • USD/JPY

    109.6100
    +0.1900 (+0.17%)
     
  • BTC-USD

    42,920.03
    -2,771.05 (-6.06%)
     
  • CMC Crypto 200

    1,075.23
    -59.15 (-5.21%)
     
  • FTSE 100

    6,903.91
    0.00 (0.00%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Does The Market Have A Low Tolerance For Globus Medical, Inc.'s (NYSE:GMED) Mixed Fundamentals?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

With its stock down 7.3% over the past three months, it is easy to disregard Globus Medical (NYSE:GMED). We, however decided to study the company's financials to determine if they have got anything to do with the price decline. Stock prices are usually driven by a company’s financial performance over the long term, and therefore we decided to pay more attention to the company's financial performance. Particularly, we will be paying attention to Globus Medical's ROE today.

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

View our latest analysis for Globus Medical

How Do You Calculate Return On Equity?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Globus Medical is:

6.8% = US$102m ÷ US$1.5b (Based on the trailing twelve months to December 2020).

The 'return' is the profit over the last twelve months. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.07 in profit.

Why Is ROE Important For Earnings Growth?

So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company’s earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

Globus Medical's Earnings Growth And 6.8% ROE

When you first look at it, Globus Medical's ROE doesn't look that attractive. A quick further study shows that the company's ROE doesn't compare favorably to the industry average of 12% either. Accordingly, Globus Medical's low net income growth of 2.5% over the past five years can possibly be explained by the low ROE amongst other factors.

Next, on comparing with the industry net income growth, we found that Globus Medical's reported growth was lower than the industry growth of 15% in the same period, which is not something we like to see.

past-earnings-growth
past-earnings-growth

Earnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Globus Medical's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

Is Globus Medical Making Efficient Use Of Its Profits?

Conclusion

Overall, we have mixed feelings about Globus Medical. Even though it appears to be retaining most of its profits, given the low ROE, investors may not be benefitting from all that reinvestment after all. The low earnings growth suggests our theory correct. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.